UNIVERSITY OF CAMBRIDGE
University Biomedical Services

Minutes

Date Wednesday, 11/10/2023
Time 10:00 AM
To Sub-Standing Committee
At [redacted]
Subject AWERB Standing Committee
Our Ref Doc.UBS.AWERB.11.10.23

Present: [redacted]

Scientists in attendance for 1a) N/A, 1b) N/A, 1c) N/A & 1d) N/A

Apologies: [redacted]

Minutes: [redacted]

1. Project Licences

a) Amendment: [redacted] was also in attendance)

The committee discussed the following:

- The inclusion of further information in regards to pain relief in the Project Harms section.
- The inclusion of information around the use of pilot studies in the Project Harms section.
- The inclusion of specific routes of administration in the Project Harms section.
- The inclusion of further justification in regards to specific models now considered necessary and the models intended for use in the Scientific Background section.
- Further clarity required in the Animal Experience section of Protocol 5 in regards to the movement of animals.
- Further information required in Protocol 6 in regards to body weight measurements.
- Consideration given to the splitting Protocol 6 into two separate protocols if it is more appropriate.
- The removal of specific wording in step 2 of Protocol 6.
- Further information required in regards to adverse effects, monitoring, control and limiting measures for specific types of agents intended for use in step 2 of Protocol 6.
- Further information included in its own step in regards to metabolic caging in step 2 of Protocol 6.
- The inclusion of humane end points for the administration of specific substances in step 2 of Protocol 6.
- Further consideration given to how the use of imaging facilities will be accomplished in regards to step 5 of Protocol 6.
- The inclusion of specific justification for the use of specific substances in the Protocol Justification section of Protocol 6.
- Further detail required to explain that when animals will be collected in the Protocol Justification section of Protocol 6.
- Further review of the number of doses listed in the dosing table in the Protocol Justification section of Protocol 6.

The committee agreed changes were needed before a draft is submitted to the Home Office

b) Amendment: [redacted]

The committee discussed the following:

- Further information required in regards to the enhanced monitoring provided in the Refinement section.
- Consideration given to whether the new objective 6 should apply to Protocols 5 and 6.
- Expansion of the explanation given around moderate severity limits in the Protocol details section of Protocol 6.
- The recommendation that the researcher checks the administration routes and the adverse effects, monitoring and humane endpoints in regards to step 4 of Protocol 6.
- The inclusion of further adverse effects if they are appropriate in regards to step 4 of Protocol 6.
- The recommendation that the researcher amends the wording in regards to step 5 of Protocol 6.
- Consideration given to the current frequency of weighing and the increase in this frequency if needed in step 5 of Protocol 6.
- The removal of points 3 and 4 from the Experimental design section of Protocol 6.
- Further clarity required in the Animal Experience section of Protocol 6.
- The inclusion of the maximum typical number of injections an animal may undergo in the Animal Experience sections of Protocols 6 and 7.
- The removal of the first paragraph in step 4 of Protocol 7 if it is not relevant.
- Further justification required in regards to the use of specific substances in regards to step 5 of Protocol 7.
- The inclusion of examples of the steroid intended for use in regards to step 5 of Protocol 7.
- The removal of point 3 from the Experimental Design section of Protocol 7.

The committee agreed changed were needed before a draft is submitted to the Home Office.

c) Amendment: [redacted]

The committee discussed the following:

- Further information required in regards to minimising harms in the Genetically altered animals section.
- Consideration given to removing specific substances from step 7 of Protocol 7 if it is no longer required. If required, further information around adverse effects, monitoring, control measures and humane endpoints similar to those in step 13 is required.
- Reordering of step 11 in Protocol 7.
- Further consideration given to adverse effects and humane endpoints in regards to specific background strains in step 12 of Protocol 7.

The committee agreed changes were needed before a draft is submitted to the Home Office.

d) Amendment: [redacted]

The committee discussed the following:

- The inclusion of specific adverse effects in regards to step 5 of Protocol 4.
- The inclusion of controls and humane endpoints for anything listed in the adverse effects section and also the action taken for specific adverse effects in regards to step 5 of Protocol 4.

- Consideration given to the inclusion of specific procedures in Protocol 5.

The committee agreed changes were needed before a draft is submitted to the Home Office.

2. Minutes of the last meeting 13/09/23

The minutes were approved.

3. Retrospective Reviews [RR]

(a) [redacted]

The committee discussed the following:

- The committee reviewed the Retrospective Review and had no comments that needed to be addressed.

4. Any other business

Non-Regulated Procedure request: [redacted] – The committee reviewed the Non-Regulated Procedure request and asked for further information in the Source, Amount and Duration of funding for this project section. The committee agreed the request would need to be updated before it could receive ethical approval.

Overseas Research Request: [redacted] – The committee reviewed the Overseas request and asked for further detail in regards to the funding available and whether this is adequate to complete the proposed work. The committee agreed the request would need to be updated before it could receive ethical approval.

5. Date of next meeting: 08/11/2023